NOVOGEN LIMITED 1 February 2016
Dear Fellow Shareholders,
It is a pleasure and a privilege to join Novogen today as Chief Executive Officer. I wanted to take the opportunity to write to you on this, my first day in the role, in order to introduce myself and to share some of my ambitions and aspirations for our company.
I trained as a medical doctor and my early career was spent working at hospitals in the UK and Australia. Since then, most of my working life has been in drug development. I have had the good fortune to work in some of the world's most successful and most innovative biotech and pharmaceutical companies.
In doing so, I have been able to help bring some significant new products to market. Nevertheless, I have remained, at heart, a physician. I have always been motivated first and foremost by a desire to apply scientific knowledge for the benefit of patients in need.
This will continue to be my driving passion at Novogen. Our company can play an important role in the treatment of patients grappling with some of the most intractable and devastating diseases known to medicine. We have a strong foundation, thanks to the work of excellent scientists over the last several years. We are well-funded, with the resources to advance each of our three lead molecules into early clinical trials. We have an exceptional team, with a level of expertise, dedication, and professionalism that has already inspired me in our early interactions. We have a diverse and highly-experienced Board of Directors, whose engagement with the company reflects their belief in its potential.
Nonetheless, the journey ahead of us is long and challenging. In my experience with the pharmaceutical sector, I have sometimes seen initially promising molecules fail to live up to expectations. But I have also seen the enormous impact that successful products can have on the lives of patients and their families, and I hope that our work in Novogen will play a comparable role in the fight against cancer. So while the task is extremely challenging, I believe that the prize is great and I look forward to pursuing those aspirations in a dynamic, entrepreneurial and passionate company such as this.
Over the coming weeks and months, I plan to review each of our three most advanced programs - Cantrixil, Anisina and Trilexium - in some detail with the team and our primary focus for 2016 will be to progress these molecules towards the clinic in the fastest and most effective way possible. My initial estimation is that Cantrixil, the most advanced of our programs, will begin recruiting patients in the second half of this year. I will also be reaching out to some of our key investors and partners to learn how we can work together more effectively and better communicate the value inherent in our business. I look forward to sharing regular updates on our progress, via announcements to the ASX and to NASDAQ for material developments and via the corporate website for topics of more general relevance.
I thank you for your ongoing support of Novogen and I look forward to an exciting and transformative year ahead for our company.
Yours sincerely,
Dr James Garner Chief Executive Officer
Novogen Limited issued this content on 01 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 31 January 2016 21:38:07 UTC
Original Document: http://www.novogen.com/pdf/160201 Novogen CEO Letter To Shareholders.pdf
